Overview

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.
Phase:
Phase 3
Details
Lead Sponsor:
Kirby Institute
Collaborator:
AbbVie
Treatments:
Ribavirin
Ritonavir